Spots Global Cancer Trial Database for immune checkpoint inhibition
Every month we try and update this database with for immune checkpoint inhibition cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML | NCT04913922 | Acute Myeloid L... | Azacitidine Inj... Nivolumab Relatlimab | 18 Years - | Ludwig-Maximilians - University of Munich | |
| REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer | NCT03610711 | Gastroesophagea... Immune Checkpoi... | Nivolumab Relatlimab | 18 Years - 99 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer | NCT03955978 | Endometrial Can... Cancer of the E... | TSR-042 Brachytherapy Endometrial bio... Blood draw for ... | 18 Years - | Washington University School of Medicine | |
| Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML | NCT04913922 | Acute Myeloid L... | Azacitidine Inj... Nivolumab Relatlimab | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity | NCT04273061 | Breast Cancer Lung Cancer Gastrointestina... Genitourinary C... Gynecologic Can... Sarcoma Unknown Primary... Head and Neck C... Skin Cancer | Atezolizumab | 18 Years - | British Columbia Cancer Agency | |
| Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder | NCT02621151 | Muscle-invasive... | Pembrolizumab Transurethral R... Gemcitabine External Beam R... | 18 Years - | NYU Langone Health | |
| Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM) | NCT04447651 | Metastatic Soli... SF3B1 Gene Muta... Spliceosome Mut... U2AF1 Gene Muta... SRSF2 Gene Muta... | Recommendation ... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer | NCT03610711 | Gastroesophagea... Immune Checkpoi... | Nivolumab Relatlimab | 18 Years - 99 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Integrative Analysis of Tumor Microenvironment and Optimization of Immunotherapy Duration in NSCL Cancer Patients | NCT04880382 | Non Small Cell ... | ICI treatment d... ICI treatment c... | 18 Years - | Institut Bergonié | |
| VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) | NCT04166383 | Metastatic Colo... Colorectal Neop... Colorectal Carc... Colorectal Canc... Colorectal Tumo... | Vascular Biogen... Nivolumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC) | NCT04638582 | Lung Cancer, No... | Pembrolizumab Carboplatin Paclitaxel Pemetrexed | 18 Years - | McGill University Health Centre/Research Institute of the McGill University Health Centre |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
